BioLineRx (BLRX) Misses Q2 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LVS
9. LRCX
10. MRK

Go back to BioLineRx (BLRX) Misses Q2 EPS by 4c

BioLineRx Reports Second Quarter 2015 Financial Results

August 20, 2015 7:00 AM EDT

TEL AVIV, Israel--(BUSINESS WIRE)-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the second quarter ended June 30, 2015.

Kinneret Savitsky, Ph.D., CEO of BioLineRx, remarked, We expect some very exciting milestones for our BL-8040 oncology platform in the coming few months. First, we expect to report top-line data, including response rates, from our Phase 2 clinical study for treating relapsed/refractory AML in the fourth quarter of 2015, following the highly encouraging results to date... More